On Thursday, Trimble Navigation Limited (NASDAQ:TRMB)’s shares inclined 0.64% to $23.62.
Trimble Navigation Limited (TRMB) declared TILOS version 9.0 time and location planning software for highways, railways, pipelines, tunnels, water engineering, and transmission line construction and other linear civil engineering projects. Trimble® TILOS merges technical and plan information into one dynamic plan, giving users more information than Gantt charts or network diagrams alone. The new version of TILOS offers better linear construction project visualization and improved integration with Primavera project administration software and Trimble Business Center – HCE office software for heavy civil construction takeoff and data preparation.
Trimble Navigation Limited provides technology solutions to enhance the work processes of office and mobile field professionals worldwide. The company’s Engineering and Construction segment offers field and office software for route selection and design; systems to guide and control construction equipment; systems to monitor, track, and manage assets, equipment, and workers; software to share and communicate data; 3D conceptual design and modeling software; BIM software for design, construction, and maintenance; integrated site layout and measurement systems; application products; integrated workplace administration services software; capital program and facility administration solutions; and field based data collection systems and software, communications systems, and back-office software.
Fulton Financial Corp (NASDAQ:FULT)’s shares dropped -1.51% to $13.05.
The Board of Directors of Fulton Financial Corporation (NASDAQ: FULT) has declared a quarterly cash dividend of nine cents per share on its common stock, payable on July 15, 2015 to shareholders of record as of July 1, 2015.
Fulton Financial Corporation, a $17.4 billion Lancaster, Pa.-based financial holding company, has about 3,700 employees and operates more than 240 branches in Pennsylvania, Maryland, Delaware, New Jersey and Virginia through six partner banks.
Fulton Financial Corporation operates as a multi-bank financial holding company that provides a range of banking and financial services to businesses and consumers. It offers personal banking services that comprise various checking account and savings deposit products, certificates of deposit, and individual retirement accounts.
At the end of Thursday’s trade, Kite Pharma Inc (NASDAQ:KITE)‘s shares surged 2.47% to $65.07.
Kite Pharma, Inc. (KITE) and bluebird bio, Inc. (BLUE) declared that they have reached a partnershipagreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, counting HPV-16 E6 TCR, presently in a Phase I study, and HPV-16 E7 TCR. The partnership brings together the powerful technologies and capabilities of these two leading immunotherapy companies.
Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.
Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, counting research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers.
Vivint Solar Inc (NYSE:VSLR), ended its Thursday’s trading session with -6.17% loss, and closed at $10.94.
Vivint Solar Inc (VSLR) declared plans to collaborate with Blackstone to provide clean, efficient solar energy to Blackstone’s portfolio of commercial and industrial properties.
Vivint Solar recently closed its first solar commercial and industrial investment fund that will enable the company to expand its solar energy offerings to commercial and industrial businesses across the U.S. Blackstone, a premier investment and advisory firm specializing in private equity, credit and hedge fund investment strategies, presently maintains in its portfolio a vast assortment of commercial and industrial properties.
Vivint Solar, Inc. provides distributed solar energy to residential customers in Arizona, California, Hawaii, Maryland, Massachusetts, New Jersey, New York, and Utah. It installs and owns solar energy systems through long-term customer contracts, such as power purchase agreements and solar energy system leases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
